MorphoSys AG (MOR) PT Set at €76.00 by Commerzbank Ag
MorphoSys AG (ETR:MOR) received a €76.00 ($88.37) price objective from Commerzbank Ag in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock. Commerzbank Ag’s price target would indicate a potential downside of 3.52% from the company’s previous close.
Other analysts also recently issued research reports about the stock. Berenberg Bank set a €68.00 ($79.07) price target on shares of MorphoSys AG and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Deutsche Bank AG set a €90.00 ($104.65) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Tuesday, August 1st. Independent Research GmbH set a €77.00 ($89.53) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Monday, July 24th. Finally, Oddo Bhf set a €76.00 ($88.37) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a report on Thursday, September 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of €79.00 ($91.86).
Shares of MorphoSys AG (MOR) opened at €78.77 ($91.59) on Tuesday. MorphoSys AG has a 1 year low of €38.14 ($44.35) and a 1 year high of €80.67 ($93.80).
TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/morphosys-ag-mor-pt-set-at-76-00-by-commerzbank-ag/1684384.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.